Cargando…

Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma

BACKGROUND: Liver cancer is the fifth most common cancer and the second cause of cancer-related deaths worldwide. Transarterial chemoembolization (TACE) is the best treatment of intermediate hepatocellular carcinoma (HCC). Doxorubicin is the most commonly used drug despite a low level of evidence. A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roth, Gaël Stéphane, Teyssier, Yann, Abousalihac, Mélodie, Seigneurin, Arnaud, Ghelfi, Julien, Sengel, Christian, Decaens, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Retrospective Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969879/ https://www.ncbi.nlm.nih.gov/pubmed/31988592 http://dx.doi.org/10.3748/wjg.v26.i3.324

Ejemplares similares

Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma
por: Roth, Gael S., et al.
Publicado: (2022)

Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis
por: Roth, Gaël S., et al.
Publicado: (2021)

Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization
por: Roth, Gael, et al.
Publicado: (2022)

Transarterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin-Loaded Tandem Drug-Eluting Embolics
por: Guiu, Boris, et al.
Publicado: (2019)

Simultaneous transarterial chemoembolization and radiofrequency ablation for large hepatocellular carcinoma
por: Duan, Feng, et al.
Publicado: (2020)

Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy
por: Miki, Izumi, et al.
Publicado: (2017)

Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization
por: Ventura, Yossi, et al.
Publicado: (2018)

Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study
por: Lei, Xue-Fen, et al.
Publicado: (2018)

Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma
por: Greco, Giorgio, et al.
Publicado: (2017)

Transarterial chemoembolization combined with radiofrequency ablation in the treatment of large hepatocellular carcinoma with stage C
por: Sun, Sha-Sha, et al.
Publicado: (2022)

Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer
por: Bian, Li-Fang, et al.
Publicado: (2020)

Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma
por: Niu, Xiang-Ke, et al.
Publicado: (2021)

Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma
por: Fukushima, Taito, et al.
Publicado: (2021)

Efficacy of intra-arterial contrast-enhanced ultrasonography during transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma
por: Shiozawa, Kazue, et al.
Publicado: (2018)

Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization
por: Wang, Zhe-Xuan, et al.
Publicado: (2020)

Identification of predictive factors for post-transarterial chemoembolization liver failure in hepatocellular carcinoma patients: A retrospective study
por: Yuan, Min, et al.
Publicado: (2022)

Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib
por: Meng, Xiao-Chun, et al.
Publicado: (2018)

Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
por: Wang, Yan-Yu, et al.
Publicado: (2023)

High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy
por: Bauer, Ulrike, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
por: Zhou, Qunfang, et al.
Publicado: (2020)

Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma
por: Chen, Lei, et al.
Publicado: (2020)

Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study
por: Wang, Zhe-Xuan, et al.
Publicado: (2020)

The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma
por: Li, Hao, et al.
Publicado: (2023)

Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation
por: Nicolini, Daniele, et al.
Publicado: (2017)

Impact of alcohol consumption on treatment outcome of hepatocellular carcinoma patients with viral hepatitis who underwent transarterial chemoembolization
por: Rattanasupar, Attapon, et al.
Publicado: (2022)

Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma
por: Kim, Jun Young, et al.
Publicado: (2016)

Liver resection versus transarterial chemoembolization for the treatment of intermediate‐stage hepatocellular carcinoma
por: Chen, Shuling, et al.
Publicado: (2019)

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2020)

The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma
por: Kaibori, Masaki, et al.
Publicado: (2021)

Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor
por: Lee, Song Yi, et al.
Publicado: (2018)

Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma
por: Song, Jeong Eun, et al.
Publicado: (2017)

Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia
por: Sherif, Hemat Afifi, et al.
Publicado: (2021)

A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
por: Ogasawara, Sadahisa, et al.
Publicado: (2015)

Latent Class Analysis of Subphenotypes in Intermediate-Stage Hepatocellular Carcinoma after Transarterial Chemoembolization
por: Chen, Siyu, et al.
Publicado: (2022)

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
por: Kloeckner, Roman, et al.
Publicado: (2015)

Doxorubicin-loaded Drug-eluting beads Versus Conventional Transarterial Chemoembolization for Nonresectable Hepatocellular Carcinoma
por: Arabi, Mohammad, et al.
Publicado: (2015)

Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma
por: Wang, Cao-ye, et al.
Publicado: (2020)

Transarterial chemoembolization combined with iodine-125 seed implantation for patients with hepatocellular carcinoma: a retrospective controlled study
por: Chen, Lei, et al.
Publicado: (2020)

Tumor enhancement ratio with unenhanced imaging is an independent prognostic factor for patients with hepatocellular carcinoma after transarterial chemoembolization
por: Yang, Xi-Yuan, et al.
Publicado: (2021)

Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus
por: Chen, Junwei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vhq0suvrk39lqojodvsa3u14ij